Neurogene Inc. (NGNE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for NGNE, including 4 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 9, 2026.
NGNE rankings
Financial highlights
Full financials- Revenue, FY2025
- $0
- Revenue growth
- -100.0%
- Net income, FY2025
- -$90.35M
- Free cash flow, FY2025
- -$78.36M
- Cash
- $78.94M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks39+40%
2026-05-172026-11-08
Mix1490d
- Other9(64%)
- SEC Filings2(14%)
- Insider1(7%)
- Analyst1(7%)
- Earnings1(7%)
Activity · 52 weeks8247 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Neurogene Inc.10-Q - Neurogene Inc. (0001404644) (Filer)
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports Third Quarter 2026 Financial Results and Highlights Recent UpdatesTopline data from Embolden™ registrational trial anticipated in 2H 2027 Presented new preclinical data highlighting the purposeful design of NGN-401 for Rett syndrome, including rapid onset and durable expression of full-length MECP2 transgene with single-stranded AAV construct NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of November 8, 2026 On track to complete PPQ runs by year-end 2026 Strong cash position provides runway into first quarter of 2029 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced thi
- PRNeurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company’s common stock to one new employee (the "Inducement Grant") on November 3, 2026 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Ru
- PRNeurogene to Participate in Upcoming Investor ConferencesNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, November 10 at 10:30 a.m. ET Stifel 2026 Healthcare Conference Format: Management will participate in a fireside chat and investor meetings Date: Wednesday, November 11 at 10:40 a.m. ET Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’
- PRNeurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett SyndromeNew data showing rapid and durable full-length MECP2 expression in vivo with single-stranded AAV support improvements observed in NGN-401 Phase 1/2 trial New in vivo data demonstrate that miRNA-based auto-regulatory technology is not responsive to endogenous MeCP2 levels on a cell-by-cell basis Preclinical data demonstrate broad CNS biodistribution following ICV administration, a routinely performed neurosurgical procedure, reinforcing NGN-401's route of delivery strategy Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, will present data related to its NGN-401 gene t
- PRNeurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual CongressNew presentations to highlight rapid transgene expression of full-length MECP2 following single-stranded AAV delivery and evaluation of miRNA-based approaches to regulating MeCP2 expression on a cell-by-cell basis Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. New preclinical data to be featured are aimed at addressing two important questi
- ANALYSTAnalyst initiated coverage on Neurogene with a new price targetAnalyst initiated coverage of Neurogene with a rating of Overweight and set a new price target of $60.00
- SECSEC Form SCHEDULE 13G filed by Neurogene Inc.SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)
- SECSEC Form SCHEDULE 13G filed by Neurogene Inc.SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the "Inducement Grants") on October 5, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Li
- INSIDERChief Executive Officer Mcminn Rachel exercised 756 shares at a strike of $25.32, increasing direct ownership by 0.06% to 1,345,063 units (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, September 15 at 1:00 p.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time. About Neurogene Neurogene (NASDAQ:NGNE) is a clinical-stage biotechnology compan
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company’s common stock to two new employees (the "Inducement Grants") on September 1, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq
- SECSEC Form SCHEDULE 13G filed by Neurogene Inc.SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)
- SECSEC Form 10-Q filed by Neurogene Inc.10-Q - Neurogene Inc. (0001404644) (Filer)
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent UpdatesData from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026 Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment Topline data from Embolden™ registrational trial anticipated in 2H 2027 NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026 Initiated PPQ campaign to support BLA submission for NGN-401; completion of PPQ runs expected by end of 2026 Extended cash
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the "Inducement Grants") on August 3, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Li
- PRNewleos Names Rohan Palekar as Board Chairman– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors – Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026072830083
- INSIDERPresident and CFO Cvijic Christine Mikail sold $173,375 worth of shares (4,800 units at $36.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the "Inducement Grants") on July 6, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi
- INSIDERPresident and CFO Cvijic Christine Mikail sold $166,586 worth of shares (4,800 units at $34.71) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- SECNeurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 424B5 filed by Neurogene Inc.424B5 - Neurogene Inc. (0001404644) (Filer)
NGNE FAQ
10 questionsWhat is the latest news on NGNE?
In the last 30 days Quantisnow tracked 7 wire items for NGNE: 4 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published on November 9, 2026.What is NGNE revenue?
Neurogene Inc. (NGNE) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is NGNE profitable?
No. Neurogene Inc. reported a net loss of $90.35M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NGNE have?
Neurogene Inc. reported $78.94M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NGNE stock trade?
Neurogene Inc. (NGNE) is listed on NASDAQ.What sector and industry is NGNE in?
Neurogene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Neurogene Inc. go public?
Neurogene Inc. (NGNE) completed its IPO in 2014.What are analysts saying about NGNE?
Across the last 8 analyst actions on Neurogene Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Analyst: Overweight with a $60.00 price target on 2026-10-08. Recent price targets range from $24.00 to $70.00.What companies are similar to NGNE?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare NGNE side-by-side with any of them on Quantisnow.How can I track NGNE on Quantisnow?
Quantisnow aggregates Neurogene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NGNE to receive live email and push alerts on every new disclosure.